Portal de Periódicos da CAPES

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management

2022; Lippincott Williams & Wilkins; Volume: 208; Issue: 1 Linguagem: Inglês

10.1097/ju.0000000000002757

1527-3792

James A. Eastham, Gregory B. Auffenberg, Daniel A. Barocas, Roger Chou, Tony Crispino, John W. Davis, Scott E. Eggener, Eric M. Horwitz, Christopher J. Kane, Erin Kirkby, Daniel W. Lin, Sean McBride, Alicia K. Morgans, Phillip M. Pierorazio, George Rodrigues, William W. Wong, Stephen A. Boorjian,

Health Systems, Economic Evaluations, Quality of Life

The summary presented herein represents Part I of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment, staging, and risk-based management in patients diagnosed with clinically localized prostate cancer. Please refer to Parts II and III for discussion of principles of active surveillance, surgery and follow-up (Part II), and principles of radiation and future directions (Part III).The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles.The Clinically Localized Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with clinically localized prostate cancer. Statements regarding risk assessment, staging, and risk-based management are detailed herein.This guideline aims to inform clinicians treating patients with clinically localized prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to further improve care for these men.